MX2014001850A - Anticuerpos que enlazan alfa-v beta-8 integrina. - Google Patents

Anticuerpos que enlazan alfa-v beta-8 integrina.

Info

Publication number
MX2014001850A
MX2014001850A MX2014001850A MX2014001850A MX2014001850A MX 2014001850 A MX2014001850 A MX 2014001850A MX 2014001850 A MX2014001850 A MX 2014001850A MX 2014001850 A MX2014001850 A MX 2014001850A MX 2014001850 A MX2014001850 A MX 2014001850A
Authority
MX
Mexico
Prior art keywords
antibodies
beta
integrin alpha
bind integrin
bind
Prior art date
Application number
MX2014001850A
Other languages
English (en)
Other versions
MX350335B (es
Inventor
Jody Lynn Baron
Jianlong Lou
James Marks
Stephen Lloyd Nishimura
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of MX2014001850A publication Critical patent/MX2014001850A/es
Publication of MX350335B publication Critical patent/MX350335B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Se proporcionan en la presente anticuerpos con alta afinidad para la subunidad ß8 de a?ß8.
MX2014001850A 2011-08-17 2012-08-17 Anticuerpos que enlazan alfa-v beta-8 integrina. MX350335B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161524708P 2011-08-17 2011-08-17
US201261646111P 2012-05-11 2012-05-11
PCT/US2012/051373 WO2013026004A2 (en) 2011-08-17 2012-08-17 Antibodies that bind integrin alpha-v beta-8

Publications (2)

Publication Number Publication Date
MX2014001850A true MX2014001850A (es) 2014-12-08
MX350335B MX350335B (es) 2017-09-04

Family

ID=47715714

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014001850A MX350335B (es) 2011-08-17 2012-08-17 Anticuerpos que enlazan alfa-v beta-8 integrina.

Country Status (13)

Country Link
US (1) US9492569B2 (es)
EP (1) EP2744823B1 (es)
JP (1) JP6093360B2 (es)
KR (1) KR102010098B1 (es)
CN (1) CN103857696B (es)
AU (1) AU2012296362B2 (es)
BR (1) BR112014003501B1 (es)
CA (1) CA2846240C (es)
ES (1) ES2643397T3 (es)
MX (1) MX350335B (es)
RU (1) RU2614252C2 (es)
SG (1) SG2014014237A (es)
WO (1) WO2013026004A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2565539C2 (ru) * 2010-02-18 2015-10-20 Те Риджентс Оф Те Юниверсити Оф Калифорния АНТИТЕЛА, НЕЙТРАЛИЗУЮЩИЕ ИНТЕГРИН ανβ8
WO2014197849A2 (en) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Anti-c10orf54 antibodies and uses thereof
RS60061B1 (sr) * 2014-06-17 2020-04-30 Medimmune Ltd Unapređena alfa-v beta-8 antitela
EP3009147A1 (en) 2014-10-16 2016-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating resistant glioblastoma
WO2017182834A1 (en) 2016-04-19 2017-10-26 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for treating resistant glioblastoma
CA3223687A1 (en) * 2016-09-29 2018-04-05 The Regents Of The University Of California Neutralizing antibodies to the .alpha.v.beta.8 integrin complex for immunotherapy
US20180346577A1 (en) * 2017-05-30 2018-12-06 The Board Of Trustees Of The Leland Stanford Junior University Treatment of neuroinflammatory disease
CA3107137A1 (en) * 2018-09-07 2020-03-12 Pfizer Inc. Anti-avb8 antibodies and compositions and uses thereof
BR112021009325A2 (pt) * 2018-11-14 2021-09-14 Arch Oncology, Inc. Anticorpo monoclonal, ou fragmento de ligação ao antígeno do mesmo; anticorpo biespecífico; método para prevenir ou tratar um câncer suscetível em um ser humano; método de ensaio de expressão de sirp¿ em células tumorais e/ou imunes; e; composição farmacêutica
WO2020210650A1 (en) 2019-04-12 2020-10-15 Medimmune, Llc Neutralization of tgf-beta or alpha-v-beta-8 integrin for s. aureus infections
TW202140554A (zh) 2020-01-27 2021-11-01 英商梅迪繆思有限公司 用於治療腎臟疾病之抗αｖβ８整聯蛋白抗體
WO2024056668A1 (en) * 2022-09-12 2024-03-21 Institut National de la Santé et de la Recherche Médicale New anti-itgb8 antibodies and its uses thereof
CN117143241B (zh) * 2023-10-26 2024-02-23 迈威(上海)生物科技股份有限公司 与人整合素蛋白itgav/itgb8特异性结合的单克隆抗体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JPH06506115A (ja) * 1991-03-14 1994-07-14 ジェネンテク，インコーポレイテッド 新規ベータインテグリンサブユニット
DE69531187T2 (de) * 1994-12-20 2004-04-22 Merck Patent Gmbh Monoklonaler Antikörper gegen das Alpha-V-Integrin
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
AU2003295411A1 (en) * 2002-11-07 2004-06-03 Celltech R & D Human monoclonal antibodies to heparanase
EP1613273B1 (en) 2003-04-11 2012-06-13 MedImmune, LLC Recombinant il-9 antibodies and uses thereof
EP1674480A4 (en) 2003-09-04 2007-06-20 Riken ANTIBODY RECOGNIZING THE REGIONAL SECTION CONTROLLING TGF-BETA ACTIVATION
HUE026132T2 (en) 2004-01-07 2016-05-30 Novartis Vaccines & Diagnostics Inc M-CSF-specific monoclonal antibody and its uses
RU2011111640A (ru) 2008-08-29 2012-10-10 Симфоген А/С (Dk) Антитела против cd5
WO2011020529A2 (en) * 2009-08-19 2011-02-24 Merck Patent Gmbh Antibodies for the detection of integrin complexes in ffpe material
RU2565539C2 (ru) * 2010-02-18 2015-10-20 Те Риджентс Оф Те Юниверсити Оф Калифорния АНТИТЕЛА, НЕЙТРАЛИЗУЮЩИЕ ИНТЕГРИН ανβ8

Also Published As

Publication number Publication date
RU2614252C2 (ru) 2017-03-24
US9492569B2 (en) 2016-11-15
CA2846240C (en) 2021-01-12
JP2015501285A (ja) 2015-01-15
KR102010098B1 (ko) 2019-08-13
ES2643397T3 (es) 2017-11-22
BR112014003501B1 (pt) 2022-02-08
EP2744823B1 (en) 2017-08-02
JP6093360B2 (ja) 2017-03-08
MX350335B (es) 2017-09-04
AU2012296362B2 (en) 2017-06-29
EP2744823A4 (en) 2015-08-12
SG2014014237A (en) 2014-07-30
RU2014109928A (ru) 2015-09-27
CN103857696A (zh) 2014-06-11
AU2012296362A1 (en) 2014-03-13
US20140271478A1 (en) 2014-09-18
BR112014003501A2 (pt) 2017-03-01
EP2744823A2 (en) 2014-06-25
CN103857696B (zh) 2017-07-04
KR20140054238A (ko) 2014-05-08
WO2013026004A3 (en) 2013-06-13
WO2013026004A2 (en) 2013-02-21
CA2846240A1 (en) 2013-02-21

Similar Documents

Publication Publication Date Title
MX2014001850A (es) Anticuerpos que enlazan alfa-v beta-8 integrina.
IL293362B1 (en) Broad-spectrum neutralizing antibodies against the AIDS virus
HRP20181646T1 (hr) Konjugati pirolobenzodiazepin - anti-psma protutijela
IL287270A (en) Anti-psgl-1 antibodies and their use
HK1203976A1 (en) Antibody against the csf-1r csf-1r
PH12014501427B1 (en) Anti-phf-tau antibodies and their uses
PT2906251T (pt) Conjugados de pirrolobenzodiazepina-anticorpo anti-cd22
LT2906252T (lt) Pirolobenzodiazepino-anti-her2 antikūno konjugatai
MX2018014178A (es) Anticuerpo anti-fgfr2.
IL230719A0 (en) highly galactosylated antibodies
EP2663334A4 (en) ANTIBODIES AGAINST INFLUENZA
MX2015003541A (es) Metodos para identificar los anticuerpos con inmunogenia reducida.
MX2014002053A (es) Anticuerpos anti -mcsp y metodos de uso.
EP2768858A4 (en) ANTI-INFLUENZA ANTIBODIES
ZA201206055B (en) Antibodies against cxcr4
WO2012149334A3 (en) Methods and compositions for the generation and use of conformation-specific antibodies
IN2012DE02272A (es)
UA72478U (ru) Применение полентара как средства фригопротекторного действия
GB201209584D0 (en) Modified antibodies

Legal Events

Date Code Title Description
FG Grant or registration